Amikacin pharmacokinetics in pediatric patients with malignancy

Area of Science:

• Pharmacology
• Pediatric Oncology
• Infectious Diseases

Background:

• Amikacin is an aminoglycoside antibiotic used to treat serious bacterial infections.
• Pediatric patients with malignancies often require antibiotic therapy, necessitating pharmacokinetic studies.
• Understanding amikacin's behavior in this specific population is vital for optimizing treatment outcomes.

Purpose of the Study:

• To evaluate the pharmacokinetics of amikacin in pediatric patients with malignancies.
• To compare different intravenous dosage regimens of amikacin.
• To determine the optimal dosing strategy for amikacin in this patient group.

Main Methods:

• Pharmacokinetic analysis of amikacin in 50 pediatric patients (1-17 years) with normal renal function.
• Administration of amikacin via intravenous infusion over 30 or 60 minutes at different dosing frequencies (every 8h or every 6h).
• Measurement of serum amikacin concentrations at various time points to determine key pharmacokinetic parameters.

Main Results:

• Administering amikacin over 30 minutes resulted in high peak serum concentrations but subtherapeutic levels at 4 hours.
• A regimen of 20 mg/kg per 24 hours, divided every 6 hours and infused over 60 minutes, achieved therapeutic concentrations.
• Key pharmacokinetic parameters included a serum half-life of 1.24 h, volume of distribution of 0.26 L/kg, and clearance of 131 ml/min per 1.73 m2. No drug accumulation or significant side effects were observed.

Conclusions:

• The optimal initial dosage regimen for amikacin in pediatric patients with malignancies appears to be 20 mg/kg per 24 hours, administered in equally divided doses every 6 hours over 60 minutes.
• Individualization of amikacin dosage is essential, guided by measured serum concentrations and bacterial pathogen susceptibility data.
• This approach ensures therapeutic efficacy while minimizing the risk of subtherapeutic levels or toxicity.